All In Biotech

Drug Trial Radar · NCT02021318

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa

A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis

Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 616 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

616

Actual

Start

Mar 12, 2014

Primary completion

Mar 23, 2018

Study completion Nov 6, 2019

Sponsor

Lead sponsor
Astellas Pharma Europe B.V.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Kyntra Bio
First posted
Dec 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to evaluate the efficacy of roxadustat compared to darbepoetin alfa in the treatment of anemia in nondialysis-dependent chronic kidney disease (NDD CKD) participants.

Conditions

  • Anemia in Chronic Kidney Disease in Non-dialysis Patients

Interventions

  • RoxadustatDrug

    Oral tablet.

  • Darbepoetin alfaDrug

    Subcutaneous or intravenous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue TherapyTime frame: Baseline to week 24

Locations

125 sites in 26 countries. Site status is shown where the registry gives one.

  • Site AT43009

    Vienna, Austria

  • Site BY37503

    Brest, Belarus

  • Site BY37501

    Grodno, Belarus

  • Site BY37506

    Minsk, Belarus

  • Site BY37507

    Minsk, Belarus

  • Site BY37505

    Minsk, Belarus

  • Site BY37502

    Vitebsk, Belarus

  • Site BG35907

    Sofia, Bulgaria

  • Site BG35927

    Sofia, Bulgaria

  • Site BG35916

    Varna, Bulgaria

  • Site HR38505

    Karlovac, Croatia

  • Site HR38504

    Slavonski Brod, Croatia

  • Site HR38510

    Zagreb, Croatia

  • Site HR38502

    Zagreb, Croatia

  • Site HR38509

    Zagreb, Croatia

  • Site CZ42008

    Liberec, Czechia

  • Site CZ42021

    Prague, Czechia

  • Site CZ42018

    Nový Jičín, CZ, Czechia

  • Site FI35810

    Helsinki, Finland

  • Site FR33004

    Avignon, France

  • Site FR33009

    Colmar, France

  • Site FR33010

    Grenoble, France

  • Site FR33062

    Limoges, France

  • Site FR33012

    Lyon, France

  • Site FR33007

    Saint-Priest-en-Jarez, France

  • Site GE99503

    Tbilisi, Georgia

  • Site GE99504

    Tbilisi, Georgia

  • Site GE99502

    Tbilisi, Georgia

  • Site DE49073

    Cloppenburg, Germany

  • Site DE49054

    Düsseldorf, Germany

  • Site DE49065

    Hamburg, Germany

  • Site DE49075

    Heilbronn, Germany

  • Site DE49057

    Hoyerswerda, Germany

  • Site HU36028

    Budapest, Hungary

  • Site HU36029

    Budapest, Hungary

  • Site HU36027

    Kistarcsa, Hungary

  • Site HU36008

    Pécs, Hungary

  • Site HU36046

    Velence, Hungary

  • Site IE35301

    Cork, Ireland

  • Site IL97202

    Be’er Ya‘aqov, Israel

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.